Cantor Colburn LLP
Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer
A compound of Formula II or a pharmaceutically acceptable salt thereof, wherein CyN is a cyclic amine group bound via a nitrogen atom; X is C or N; R1 and R2 are each independently a halogen, CN, CF3, CHF2, CH2F, a C1-C10alkyl group, a C1-C10alkoxy group, a di(C1-C5alkyl)amino; m and n are each independently 1, 2, or 3, and represents either a single bond or a double bond, wherein the racemic mixture of 3-(4-(4-chlorophenyl)thiazol-2-yl)-1-(2-ethyl-5-methoxyphenyl)-6-(2-methylprop-1-en-1-yl)-5-(piperazine-1-carbonyl)pyridin-2(1H)-one atropisomers is excluded.
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
A C A C C C A A
A61P C07B A61K C07D C07D C07D A61P A61K
inventional additional inventional inventional inventional inventional inventional inventional
Kyle Ryan Yuhong Natalia Surendra Ajit Rajan Li Jason Matthew Mindy Irene Emily Andrew Louis Xiaodong Anton Min Wei Matthew Matthew Brian
Brimacombe Fang Martinez Karavadhi Jadhav Pragani Liu Rohde Davis McIver Wang Simeonov Shen Zhao Hall Boxer